![]() |
![]() |
![]() |
![]() |
FDA Home Page | Search
FDA Site
| FDA A-Z Index | Contact
FDA
![]()
The HPFB is authorized to disclose non-public information to US FDA regarding products regulated by HPFB as part of cooperative law enforcement or cooperative regulatory activities.
It is the information management policy of the HPFB to treat all information provided by an applicant in support of an application, including the notification process, as confidential information. HPFB’s reviewers and assessment reports are also considered confidential information. More specifically, the HPFB treats all information received as if it were confidential information for purposes of the Access to Information Act and the Privacy Act. HPFB will obtain the written consent of the applicant prior to providing any information from submission filed in support of seeking market authorization in Canada. The HPFB will advise the FDA at the time of the sharing of the information of the nature of the information it is providing.
US FDA understands that some of the information it receives from HPFB may include non-public information exempt from public disclosure under Canadian laws, such as confidential commercial information; trade secret information; personal privacy information; law enforcement information; or internal advice and recommendations. US FDA understands that this non-public information is shared in confidence, and that Canada considers it critical that US FDA maintains the confidentiality of the information. Public disclosure of this information by US FDA could seriously jeopardize any further scientific and regulatory interactions between USFDA and Health Canada. US FDA of the non-public status of the information at the time the information is shared.
Therefore, the US FDA certifies that it:
______/s/_______ Date: Nov 18, 2003
|
![]()